CanX

CanX is a biotechnology company focused on the development of novel cannabinoid-based therapeutics for the treatment of inflammatory and fibrotic diseases. The company leverages its expertise in cannabinoid receptor pharmacology to design small molecules that selectively target CB1 and CB2 receptors to modulate immune responses and tissue repair. CanX's lead programs are currently in the pre-clinical stage, with a focus on addressing high unmet medical needs in chronic pain and organ fibrosis. By optimizing the therapeutic potential of the endocannabinoid system, CanX aims to provide safer and more effective alternatives to current standard-of-care treatments.